Benefits of real-time CGM

Dexcom G6 is suitable for anyone with type 1 diabetes over the age of 2 years. Whether treated with multiple daily injections or insulin pump therapy, they can benefit from real-time continuous glucose monitoring (rt-CGM).  

 

Image
hero collage

Who Can Benefit?

In line with NICE Guidance, you should consider Dexcom CGM for your patients including:  

NICE Guidelines for Adults

NICE Guidelines for Adults

NICE now recommends that adults with type 1 diabetes are offered a choice of glucose sensor, including rt-CGM.3

Children & Young People

Children & Young People

Real-time continuous glucose monitoring (rt-CGM) should be offered to all children and young people with type 1 diabetes.4

Type 2 diabetes

Type 2 diabetes

For people with insulin treated type 2 diabetes, NICE now recommends that rt-CGM can be considered as an alternative to isCGM (Intermittently Scanned Continuous Glucose Monitoring).5 

More Insight Than Monitoring Alone

2.2-Slot-3-more-Insight-than-Monitoring-Alone_625-x-230

Unlike a single reading from a blood glucose meter, rt-CGM provides dynamic information about the direction of glucose change, giving your patient continuous and timely feedback on nutrition, activity, and insulin requirements to help make informed diabetes treatment decisions. CGM is a powerful therapy management tool that can inform better diabetes treatment decisions, ultimately leading to tighter glycaemic control, than using a blood glucose meter alone.1 

Accessing Dexcom G6 for Your Clinic

Image
slot 5

In 2020, NICE published a medical innovation briefing (MIB) on the Dexcom G6 CGM system for real-time continuous glucose monitoring. MIBs are NHS-commissioned NICE advice designed to support NHS and social care commissioners and staff who are considering using new medical devices and other medical or diagnostic technologies. 

The Dexcom G6 was proven to be a highly cost-effective management option compared to finger sticking for T1D patients with elevated HbA1c levels. This falls well below the NICE willingness to pay threshold of £20,000 per QALY gained, at £9,558 per QALY gained. Based on the NHS funding criteria, it is estimated that up to 70% of patients with T1D may be eligible for the Dexcom G6.2 

Please refer to the Diabetes UK. Type 1 Diabetes Technology: A Consensus Guideline for further details on identifying patients that could benefit from Continuous Glucose Monitoring (CGM) technology such as the Dexcom G6. 


1 Pettus J, Price DA, Edelman SV. How Patients with Type 1 Diabetes Translate Continuous Glucose Monitoring Data into Diabetes Management Decisions. Endocr Pract. 2015;:1-25.

2 Roze, et.al Diabetes care, 43(10), 2411–2417.